Addressing COVID-19 challenges: Quick wins for medical affairs leaders

Posted by Sunil John on Fri, May 08, 2020

Access COVID-19 resources

The current COVID-19 crisis has rapidly changed the face of the world and the pharmaceutical industry landscape. Virtual trials, large-scale use of telemedicine and non-personal engagements are a few such changes that the pharmaceuticals world is experiencing, and pharma companies need to adapt swiftly.


>
Read More

How should biopharma companies prioritize their pipeline programs during COVID-19?

Posted by Padma Gunda on Wed, Apr 08, 2020

Jared Selsberg co-wrote this blog post with Padma Gunda

Access COVID-19 resources

Independent of the current pandemic, life sciences companies frequently reevaluate their product pipeline programs on a variety of dynamic clinical and commercial factors. With COVID-19 reshaping healthcare and introducing widespread clinical trial delays, the calculus for pipeline prioritization has changed. When reprioritizing programs now, we believe that pharma companies should focus on trials for life-threatening conditions, protect patient safety and limit the use of hospital resources.


>
Read More

COVID-19 Clinical Development: What's in the Pipeline to Address the SARS-CoV-2 Pandemic?

Posted by Kristyn Feldman on Tue, Mar 24, 2020

Parul Rewari, Cody Powers, Judith Kulich and Amit Pangasa co-wrote this blog post with Kristyn Feldman.

As nations around the globe are hit hard by the novel coronavirus pandemic, many are asking the same question: What treatments or preventions are in the pipeline that may address COVID-19? Researchers the world over have launched numerous research, preclinical and clinical-stage programs in an effort to identify vaccines and treatments that can tackle the virus or to find treatments that mediate the downstream effects of the virus.


>
Read More